Resumen
La ivermectina para la prevención y el tratamiento de la COVID-19
Maria Popp1, Stefanie Reis1, Selina Schießer1, Renate Ilona Hausinger2, Miriam Stegemann3, Maria-Inti Metzendorf4, Peter Kranke1, Patrick Meybohm1, Nicole Skoetz5, Stephanie Weibel1
Filiación de los autores
1Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Wuerzburg, Alemania.2Department of Nephrology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Alemania. 3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Alemania. 4Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Duesseldorf, Düsseldorf, Alemania. 5Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Alemania.
DOI
Cita
Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, et al. La ivermectina para la prevención y el tratamiento de la COVID-19. Emergencias. 2023;35:381-3
